Serum magnesium and risk of new onset heart failure in men: the Kuopio Ischemic Heart Disease Study

European Journal of Epidemiology

Volumn 31, Issue 10, 2016, Pages 1035-1043

  Kunutsor, Setor K ^a   Khan, Hassan ^b   Laukkanen, Jari A ^c,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Central Finland Central Hospital   (Finland)

Author keywords

Heart failure; Risk factor; Serum magnesium

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; POTASSIUM; TRIACYLGLYCEROL; ZINC; BIOLOGICAL MARKER;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; FINLAND; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL ACTIVITY; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; SMOKING; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE; ZINC BLOOD LEVEL; BLOOD; MIDDLE AGED; RISK FACTOR;

ADULT; BIOMARKERS; FINLAND; HEART FAILURE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84970016176     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0164-4     Document Type: Article

References (48)

1. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i3–14. doi:10.1093/ndtplus/sfr163.
2. Romani AM. Cellular magnesium homeostasis. Arch Biochem Biophys. 2011;512(1):1–23. doi:10.1016/j.abb.2011.05.010.
3. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003;24(2):47–66.
4. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294(1–2):1–26.
5. Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87(4):820–7. doi:10.1038/ki.2014.331.
6. Joosten MM, Gansevoort RT, Bakker SJ, Group PS. Low plasma magnesium and risk of developing chronic kidney disease: results from the PREVEND Study. Kidney Int. 2015;87(6):1262–3. doi:10.1038/ki.2015.33.
7. Misialek JR, Lopez FL, Lutsey PL, et al. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans-Atherosclerosis Risk in Communities (ARIC) Study. Circ J Off J Jpn Circ Soc. 2013;77(2):323–9.
8. Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, Folsom AR. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;160(3):464–70. doi:10.1016/j.ahj.2010.06.012.
9. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998;136(3):480–90.
10. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98(1):160–73. doi:10.3945/ajcn.112.053132.
11. Ohira T, Peacock JM, Iso H, Chambless LE, Rosamond WD, Folsom AR. Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2009;169(12):1437–44. doi:10.1093/aje/kwp071.
12. Leone N, Courbon D, Ducimetiere P, Zureik M. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology. 2006;17(3):308–14. doi:10.1097/01.ede.0000209454.41466.b7.
13. Lutsey PL, Alonso A, Michos ED, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 2014;100(3):756–64. doi:10.3945/ajcn.114.085167.
14. Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol. 1991;53:299–307. doi:10.1146/annurev.ph.53.030191.001503.
15. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res. 1988;20(1–2):46–50.
16. Karppi J, Kurl S, Makikallio TH, Ronkainen K, Laukkanen JA. Serum beta-carotene concentrations and the risk of congestive heart failure in men: A population-based study. Int J Cardiol. 2013;. doi:10.1016/j.ijcard.2012.12.072.
17. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. doi:10.1093/eurheartj/ehs104.
18. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–11.
19. Saaranen M, Suistomaa U, Kantola M, Saarikoski S, Vanha-Perttula T. Lead, magnesium, selenium and zinc in human seminal fluid: comparison with semen parameters and fertility. Hum Reprod. 1987;2(6):475–9.
20. Kunutsor SK, Laukkanen JA. Serum zinc concentrations and incident hypertension: new findings from a population-based cohort study. J Hypertens. 2016;. doi:10.1097/HJH.0000000000000923.
21. Laukkanen JA, Laaksonen D, Lakka TA, et al. Determinants of cardiorespiratory fitness in men aged 42–60 years with and without cardiovascular disease. Am J Cardiol. 2009;103(11):1598–604. doi:10.1016/j.amjcard.2009.01.371.
22. Kunutsor SK, Khan H, Laukkanen JA. Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study. Diabetologia. 2015;58(5):961–7. doi:10.1007/s00125-015-3520-0.
23. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer; 2000.
24. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10(7):1025–35.
25. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
27. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87. doi:10.1002/(SICI)1097-0258(19960229)15:4<361:AID-SIM168>3.0.CO;2-4.
28. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21. doi:10.1002/sim.4085.
29. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res. 2004;17(2):126–36.
30. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem. 2002;238(1–2):163–79.
31. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22(3):228–36. doi:10.1053/euhj.2000.2289.
32. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5. doi:10.1161/01.CIR.0000072767.89944.6E.
33. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail. 2011;4(6):740–6. doi:10.1161/CIRCHEARTFAILURE.111.962688.
34. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.
35. Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet. 2010;6(8). doi:10.1371/journal.pgen.1001045.
36. King JL, Miller RJ, Blue JP Jr, O’Brien WD Jr, Erdman JW Jr. Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits. Nutr Res. 2009;29(5):343–9. doi:10.1016/j.nutres.2009.05.001.
37. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77(2):392–7.
38. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation. 1989;79(3):674–86.
39. Hruby A, O’Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging. 2014;7(1):59–69. doi:10.1016/j.jcmg.2013.10.006.
40. Zhang W, Iso H, Ohira T, Date C, Tamakoshi A, Group JS. Associations of dietary magnesium intake with mortality from cardiovascular disease: the JACC study. Atherosclerosis. 2012;221(2):587–95. doi:10.1016/j.atherosclerosis.2012.01.034.
41. Guasch-Ferre M, Bullo M, Estruch R, et al. Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr. 2014;144(1):55–60. doi:10.3945/jn.113.183012.
42. Al-Delaimy WK, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr. 2004;23(1):63–70.
43. Xu T, Sun Y, Xu T, Zhang Y. Magnesium intake and cardiovascular disease mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;167(6):3044–7. doi:10.1016/j.ijcard.2012.11.090.
44. Joosten MM, Gansevoort RT, Mukamal KJ, et al. Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr. 2013;97(6):1299–306. doi:10.3945/ajcn.112.054114.
45. Gyamlani G, Parikh C, Kulkarni AG. Benefits of magnesium in acute myocardial infarction: timing is crucial. Am Heart J. 2000;139(4):703.
46. Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res. 2011;24(4):163–80. doi:10.1684/mrh.2011.0292.
47. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014;9(11):e112558. doi:10.1371/journal.pone.0112558.
48. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. doi:10.1371/journal.pone.0124653.